Hereditary multiple exostoses: are there new plausible treatment strategies?

References

• Jones KB. Glycobiology and the growth plate: current concepts in Multiple Hereditary Exostoses. J Pediatr Orthop. 2011;31:577–586.
   PubMed Web of Science ®Google Scholar
• Porter DE, Simpson AHRW. The neoplastic pathogenesis of solitary and multiple osteochondromas. J Pathol. 1999;188:119–125.
   PubMed Web of Science ®Google Scholar
• Stieber JR, Dormans JP. Manifestations of hereditary multiple exostoses. J Am Acad Orthop Surg. 2005;13:110–120.
   PubMed Web of Science ®Google Scholar
• Porter DE, Lonie L, Fraser M, et al. Severity of disease and risk in malignant change in hereditary multiple exostoses. J Bone Joint Surg Br. 2004;86:1041–1046.
   PubMedGoogle Scholar
• Huegel J, Sgariglia F, Enomoto-Iwamoto M, et al. Heparan sulfate in skeletal development, growth, and pathology: the case of Hereditary Multiple exostoses. Dev Dyn. 2013;242:1021–1032.
   PubMed Web of Science ®Google Scholar
• Pacifici M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. Matrix Biol. 2018.
   PubMedGoogle Scholar
• Cheung PK, McCormick C, Crawford BE, et al. Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity. Am J Hum Genet. 2001;69:55–66.
   PubMed Web of Science ®Google Scholar
• Hecht JT, Hogue D, Strong LC, et al. Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome 11 and loss of heterozygosity for EXT-linked markers on chromosome 11 and 8. Am J Hum Genet. 1995;56:1125–1131.
   PubMed Web of Science ®Google Scholar
• Anower-E-Khuda MF, Matsumoto K, Habuchi H, et al. Glycosaminoglycans in the blood of hereditary multiple exostoses patients: half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. Glycobiology. 2013;23:865–876.
   PubMed Web of Science ®Google Scholar
• Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446:1030–1037.
   PubMed Web of Science ®Google Scholar
• Billings PC, Pacifici M. Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries. Connect Tissue Res. 2015;56:272–280.
   PubMed Web of Science ®Google Scholar
• Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Prospect Biol. 2011;3:a004952.
   PubMed Web of Science ®Google Scholar
• Mooij HL, BernelotMoens SJ, Gordts PL, et al. Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans. J Lipid Res. 2015;56:665–673.
   PubMed Web of Science ®Google Scholar
• Goud AL, de Lange J, Scholtes VA, et al. Pain, physical and social functioning, and quality of life in individuals with multiple hereditary exostoses in The Netherlands: a national cohort study. J Bone Joint Surg Am. 2012;94:1013–1020.
   PubMed Web of Science ®Google Scholar
• Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135–140.
   PubMed Web of Science ®Google Scholar
• Bovee JV, Cleton-Jansen A-M, Wuyts W, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcoma. Am J Hum Genet. 1999;65:689–698.
   PubMed Web of Science ®Google Scholar
• Hecht JT, Hayes E, Haynes R, et al. Differentiation-induced loss of heparan sulfate in human exostosis derived chondrocytes. Differentiation. 2005;73:212–221.
   PubMed Web of Science ®Google Scholar
• Jones KB, Piombo V, Searby C, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci USA. 2010;107:2054–2059.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Irie F, Mackem S, et al. A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci USA. 2010;107:10932–10937.
   PubMed Web of Science ®Google Scholar
• Huegel J, Mundy C, Sgariglia F, et al. Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple exostoses. Dev Biol. 2013;377:100–112.
   PubMed Web of Science ®Google Scholar
• Sgariglia F, Candela ME, Huegel J, et al. Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice. Bone. 2013;57:220–231.
   PubMed Web of Science ®Google Scholar
• Bovee JV. EXTra hit for mouse osteochondroma. Proc Natl Acad Sci USA. 2010;107:1813–1814.
   PubMed Web of Science ®Google Scholar
• Salazar VS, Gamer LW, Rosen V. BMP signaling in skeletal development, disease and repair. Nat Endocrinol. 2016;12:203–221.
   PubMed Web of Science ®Google Scholar
• Sinha R, Mundy C, Bechtold T, et al. Unsuspected osteochondroma-like outgrowths in the cranial base of Hereditary Multiple exostoses patients and modeling and treatment with a BMP antagonist in mice. PLoS Genetics. 2017;13:e1006742.
   PubMed Web of Science ®Google Scholar
• Ohkawara B, Iemura S, ten Dijke P, et al. Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol. 2002;12:205–209.
   PubMed Web of Science ®Google Scholar
• Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237:295–302.
   PubMedGoogle Scholar
• Inubushi T, Nazawa S, Matsumoto K, et al. Aberrant perichondrial BMP signaling mediates multiple osteochondromagenesis in mice. J Clin Inv Insight. 2017;2:e90049.
   PubMed Web of Science ®Google Scholar
• Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med. 2008;14:1363–1369.
   PubMed Web of Science ®Google Scholar
• Boergermann JH, Kopf J, Yu PB, et al. Dorsomorphin and LDN-193189 inhibit BMP-mediated samd, p38 and Akt signaling in C2C12 cells. Int J Biochem Cell Biol. 2010;42:1802–1807.
   PubMed Web of Science ®Google Scholar
• Ao A, Hao J, Hopkins CR, et al. DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS ONE. 2012;7:e41627.
   PubMed Web of Science ®Google Scholar
• Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TFGβ and BMP pathways. Cell Signal. 2011;23:1831–1842.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Kubilus JK, Crochiere ML, et al. Identification of unique molecular subdomains in the perichondrium and periosteum and their role in regulating gene expression in the underlying chondrocytes. Dev Biol. 2008;321:162–174.
   PubMed Web of Science ®Google Scholar
• Colnot C, Lu C, Hu D, et al. Distinguishing the contributions of the perichondrium, cartilage, and vascular endothelium to skeletal development. Dev Biol. 2004;269:55–69.
   PubMed Web of Science ®Google Scholar
• Buckland RA, Collinson JM, Graham E, et al. Antagonistic effects of FGF4 on BMP induction of apoptosis and chondrogenesis in the chick limb bud. Mech Dev. 1998;71:143–150.
   PubMed Web of Science ®Google Scholar
• Yoon BS, Pogue R, Ovchinnikov DA, et al. BMPs regulate multiple aspects of growth plate chondrogenesis through opposing actions of FGF pathways. Development. 2006;133:4667–4678.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Chan YY, Kawanami A, et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol. 2009;29:5843–5857.
   PubMed Web of Science ®Google Scholar
• Day TF, Guo X, Garrett-Beal L, et al. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739–750.
   PubMed Web of Science ®Google Scholar
• Hill TP, Spater D, Taketo MM, et al. Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8:727–738.
   PubMed Web of Science ®Google Scholar
• Zhou S, Xie Y, Tang J, et al. FGFR3 deficiency causes multiple chondroma-like lesions by upregulating hedgehog signaling. PLoS Genetics. 2015;11:e1005214.
   PubMed Web of Science ®Google Scholar
• Wehenkel M, Corr M, Guy CS, et al. Extracellular signal-regulated kinase signaling in CD4-expressing cells inhibits osteochondromas. Front Immunol. 2017;8:1–11.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015;29:1463–1486.
   PubMed Web of Science ®Google Scholar
• Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Prospect Biol. 2013;5:1–24.
   Web of Science ®Google Scholar
• Li S, Christensen C, Kohler LB, et al. Agonists of fibroblast growth factor receptor induce neurite outgrowth and survival of cerebellar granule neurons. Develop Neurobiol. 2009;69:837–854.
   PubMed Web of Science ®Google Scholar
• Ge H, Tan L, Wu P, et al. Poly-L-ornithine promotes preferred differentiation of neural stem/progenitor cells via ERK signaling pathway. Sci Rep. 2015;5:15535.
   PubMed Web of Science ®Google Scholar
• Vortkamp A, Lee K, Lanske B, et al. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science. 1996;273:613–622.
   PubMed Web of Science ®Google Scholar
• Koyama E, Leatherman JL, Noji S, et al. Early chick limb cartilaginous elements possess polarizing activity and express Hedgehog-related morphogenetic factors. Dev Dynam. 1996;207(3):344–354.
   PubMed Web of Science ®Google Scholar
• Koziel L, Kunath M, Kelly OG, et al. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell. 2004;6:801–813.
   PubMed Web of Science ®Google Scholar
• Koyama E, Young B, Nagayama M, et al. Conditional Kif3a ablation causes abnormal hedgehog signaling topography, growth plate dysfunction, and excessive bone and cartilage formation during mouse skeletogenesis. Development. 2007;134:2159–2169.
   PubMed Web of Science ®Google Scholar
• Xie J, Bartels CM, Barton SW, et al. Targeting hedgehog signaling in cancer: research and clinical developments. Onco Targets Ther. 2013;6:1425.
   PubMed Web of Science ®Google Scholar
• Mundy C, Bello A, Sgariglia F, et al. HhAntag, a hedgehog signaling antagonist, suppresses chondrogenesis and modulates canonical and non-canonical BMP signaling. J Cell Physiol. 2016;231:1033–1044.
   PubMed Web of Science ®Google Scholar
• Silapunt S, Chen L, Midgen MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016;8:375–382.
   PubMed Web of Science ®Google Scholar
• Fux L, Ilan N, Sanderson RD, et al. Heparanase: busy at the cell surface. Trends Sci. 2009;34:511–519.
   PubMed Web of Science ®Google Scholar
• Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med. 2007;11:427–452.
   PubMed Web of Science ®Google Scholar
• Patel VN, Knox SM, Likar KM, et al. Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development. 2007;134:4177–4186.
   PubMed Web of Science ®Google Scholar
• Trebicz-Geffen M, Robinson D, Evron Z, et al. The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. Int J Exp Path. 2008;89:321–331.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang X, Yamagata S, et al. Involvement of Ext and heparanase in migration of mouse FBJ osteosarcoma cells. Mol Cell Biochem. 2013;373:63–72.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Friedmann Y. Molecula properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin, Inv. 2001;108:341–447.
   PubMed Web of Science ®Google Scholar
• Huegel J, Enomoto-Iwamoto M, Sgariglia F, et al. Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage. A mechanism possibly involved in Hereditary Multiple exostoses. Am J Path. 2015;185:1676–1685.
   PubMed Web of Science ®Google Scholar
• Ritchie JP, Ramani VC, Ren Y, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. Clin Cancer Res. 2011;17:1382–1393.
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Lanzi C, Tortoreto M, et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone or in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol. 2013;85:1424–1432.
   PubMed Web of Science ®Google Scholar
• Phan AQ, Pacifici M, Esko JD. Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference. Conn Tissue Res. 2018;59:85–98.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hsieh PH, Xu Y, et al. Synthesis of 3-O-sulphated oligosaccharides to understand the relationship between structures and functions of heparan sulfate. J Am Chem Soc. 2017;139:5249–5256.
   Web of Science ®Google Scholar
• Miller RL, Wei W, Schworer R, et al. Composition, sequencing and ion mobility mass spectrometry of heparan sulfate-like octasaccahrides isomers differing in glucuronic and iduronic acid content. Eur J Mass Spectrometry. 2015;21:245–254.
   PubMed Web of Science ®Google Scholar
• Schultz V, Suflita M, Liu X, et al. Heparan sulfate domains required for fibroblast growth factor 1 and 2 signaling through fibroblast growth factor receptor 1c. J Biol Chem. 2017;292:2495–2509.
   PubMed Web of Science ®Google Scholar
• Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell. 2014;157:255–266.
   PubMed Web of Science ®Google Scholar
• Sucov HM, Evans RM. Retinoic acid and retinoic acid receptors in development. Mol Neurobiol. 1995;10:169–184.
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Garcha K, Karamboulas K, et al. BMP action in skeletogenesis involves attenuation of retinoid signaling. J Cell Biol. 2006;174:101–113.
   PubMed Web of Science ®Google Scholar
• Weston AD, Chandraratna RAS, Torchia J, et al. Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol. 2002;158:39–51.
   PubMed Web of Science ®Google Scholar
• Pacifici M, Cossu G, Molinaro M, et al. Vitamin A inhibits chondrogenesis but not myogenesis. Exp Cell Res. 1980;129:469–474.
   PubMed Web of Science ®Google Scholar
• Shimono K, Tung W-E, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nature Med. 2011;17:454–460.
   PubMed Web of Science ®Google Scholar
• Pacifici M. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Bone. 2018;109:267–275.
   PubMed Web of Science ®Google Scholar
• Inubushi T, Lemire I, Irie F, et al. Palovarotene inhibits osteochondroma formation in a mouse model of multiple hereditary exostoses. J Bone Min Res. 2018;33:658–666.
   PubMed Web of Science ®Google Scholar
• Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mous emodel of muscular dystrophy. Science. 2016;351:400–403.
   PubMed Web of Science ®Google Scholar
• Zuntini M, Pedrini E, Parra A, et al. Genetic models of osteochondroma onset and neoplastic progression: evidence for mechanisms alternative to EXT genes inactivation. Oncogene. 2010;29:3827–3834.
   PubMed Web of Science ®Google Scholar
• Ge X, Tsang K, He L, et al. NFAT restricts osteochondroma formation from entheseal progenitors. J Clin Inv Insight. 2016;1:e86254.
   PubMed Web of Science ®Google Scholar
• Nilsson O, Parker EA, Hedge A, et al. Gradients of bone morphogenetic protein-related gene expression across the growth plate. J Endocrinol. 2007;193:75–84.
   PubMed Web of Science ®Google Scholar